Pharmacotherapy for aphasia

Clinical Neurology

Volumn 47, Issue 11, 2007, Pages 859-861

  Tanaka, Yutaka ^a  

^a Tanaka Clinic   (Japan)

Author keywords

Aphasia; Neurochemistry; Neuropharmacology; Neurotransmitter; Pharmacotherapy

Indexed keywords

BROMOCRIPTINE;

APHASIA; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; CONFERENCE PAPER; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; HUMAN; LANGUAGE DISABILITY; PERSEVERATION; VERBAL MEMORY;

APHASIA; CHOLINERGIC AGENTS; DOPAMINE AGENTS; HUMANS; SEROTONIN AGENTS;

EID: 38549130274     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Tanaka Y, Bachman DL: Pharmacotherapy of aphasia. In Neurobehavior of language and cognition. Studies of normal aging and brain damage, ed by Conner LT, Obler LK, Kluwer Academic Publishers, Boston-Dordrecht-London, 2000, pp 159-176
2. Japanese source
3. Albert ML, Bachman DL, Morgan A, et al: Pharmacotherapy for aphasia. Neurology 1988; 38: 877-879
4. Enderby P, Broeckx J, Hospers W, et al: Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study. Clin Neuropharmacol 1994; 17: 320-331
5. Water-Batson D, Curtis S, Natarajan R, et al: A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 2001; 32: 2093-2098
6. Japanese source
7. Tanaka Y, Albert ML, Fujita K, et al: Treating perseveration improves naming in aphasia. Brain Lang 2006; 99: 57-58
8. Kessler J, Thiel A, Karbe H, et al: Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 2000; 31: 2112-2116
9. Small SL: Pharmacotherapy of aphasia: a critical review. Stroke 1994; 25: 1282-1289